Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aduro BioTech has entered into its second agreement with Janssen Biotech, granting an exclusive, worldwide license to certain product candidates designed to treat lung cancer and certain other cancers based on its novel LADD immunotherapy platform.
Subscribe to our email newsletter
As part of the deal, Aduro will receive a $30m up-front payment and is also eligible to receive significant development, regulatory and commercialization milestone payments up to a potential total of $817m.
Additionally, Aduro will receive high single-digit to double-digit tiered royalties on worldwide net sales upon successful launch and commercialization.
The deal will see Janssen have exclusive rights to develop and commercialize LADD product candidates in lung cancer as well as assume responsibility for all research, development, manufacturing, regulatory and commercialization activities for the licensed products.
Upon request, Aduro may provide assistance in any of these areas and will receive additional fees for these support activities.
Aduro chairman, president and chief executive officer Stephen Isaacs said since the initial agreement with Janssen in May 2014 for new immunotherapies for prostate cancer, they have been terrific partners and the company has established a strong collaboration focused on advancing its technologies forward in their licensed indications.
"We believe our LADD technology also offers tremendous promise as a potential treatment for lung cancer and we are pleased to expand our relationship with Janssen, a company with significant experience and resources focused in both lung and prostate cancer," Isaacs said.
"Separately, Aduro continues to make progress with our broad array of immunotherapy platforms in a number of other oncology indications, including pancreatic cancer, mesothelioma and glioblastoma among others."